Biomarker Analysis Services for Shock
Ace Therapeutics offers specialized biomarker analysis services exclusively focused on supporting drug discovery and preclinical development for Shock research. Our comprehensive biomarker panel is designed to advance understanding of disease pathophysiology, providing in-depth insights into the molecular and cellular mechanisms underlying Shock. Please note: all services are strictly limited to research and preclinical applications and do not include clinical diagnostic services.
Effective therapeutic intervention in Shock begins with the precise identification of relevant biomarkers. At Ace Therapeutics, our biomarker discovery and identification services form the foundation of robust drug development pipelines. We utilize systematic screening and validation strategies to uncover and characterize novel biomarkers associated with Shock pathophysiology. Our process integrates high-throughput screening, literature mining, and bioinformatic analysis to generate candidate lists, followed by rigorous experimental validation to ensure relevance and reproducibility.
Multi Omics: Our multi-omics approach leverages cutting-edge technologies in genomics, transcriptomics, proteomics, and metabolomics to provide a comprehensive systems-level understanding of Shock. By interrogating DNA, RNA, protein, and metabolite profiles, we capture the complex interplay of biological processes involved in immune activation, inflammation, apoptosis, and cellular stress responses. This integrated strategy enables the identification of biomarkers reflective of key pathways implicated in Shock, such as cytokine signaling, acute-phase responses, and immune cell activation.
Candidate Validation: We employ robust validation strategies to confirm the association of candidate biomarkers with Shock pathophysiology. Preliminary screening includes quantitative and qualitative analyses in relevant preclinical models, with subsequent prioritization based on specificity, sensitivity, biological relevance, and reproducibility. Criteria for advancing candidates include strong mechanistic links to Shock, consistency across experimental systems, and potential utility in monitoring therapeutic interventions.
Diverse Technological Platforms: Ace Therapeutics develops custom biomarker assays tailored to project-specific requirements, utilizing a diverse array of technological platforms. Our laboratory infrastructure supports adaptation and optimization of assays for various detection formats, ensuring compatibility with different sample types and analytical needs. Platforms include immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and advanced histopathology and imaging systems.
Immunoassays: We offer quantitative and qualitative immunoassays, including ELISA, chemiluminescent assays, and multiplex bead-based platforms, for sensitive detection of protein biomarkers such as cytokines and enzymes.
Mass Spectrometry: Our LC-MS/MS platforms enable highly specific and sensitive quantification of proteins, metabolites, and small molecules relevant to Shock pathophysiology.
Flow Cytometry: Multiparametric flow cytometry is utilized for the characterization and quantification of immune cell subsets, activation markers, and intracellular proteins.
Molecular Diagnostics: We perform gene expression and nucleic acid quantification using RT-qPCR, digital PCR, and next-generation sequencing to assess mRNA and DNA-based biomarkers.
Histopathology And Imaging: Immunohistochemical staining, digital pathology, and advanced imaging modalities are employed for spatial localization and quantification of biomarkers within tissues.
Rigorous Method Validation: All biomarker assays undergo rigorous validation in accordance with established research guidelines, including assessment of specificity, sensitivity, linearity, reproducibility, and robustness. Quality control measures are implemented at every stage to ensure data integrity, including the use of appropriate controls, calibration standards, and inter-assay comparisons.
Our quantitative analysis capabilities encompass absolute and relative quantification of biomarker levels across a range of biological matrices. We apply validated protocols to generate high-quality, reproducible data that inform therapeutic decision-making during preclinical Shock research.
Sample Analysis: We handle a variety of sample types, including serum, plasma, tissue lysates, and cell culture supernatants. Each sample is processed using standardized protocols to preserve biomarker integrity, and all analyses are conducted under stringent quality assurance procedures to minimize variability and ensure data reliability.
High Throughput Capabilities: High-throughput, multiplexed analytical platforms enable simultaneous measurement of multiple biomarkers from limited sample volumes, increasing efficiency and conserving valuable preclinical specimens. Our workflow supports rapid data generation, facilitating timely decision-making in Shock-focused drug discovery projects.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| caspase 3 (CASP3) | Caspase 3 (CASP3) is a cysteine-aspartic acid protease that plays a central role in the execution phase of apoptosis, the programmed cell death process. It is synthesized as an inactive proenzyme (zymogen) and is activated by proteolytic cleavage in response to pro-apoptotic signals. Once activated, caspase 3 cleaves various cellular substrates, including structural and regulatory proteins, leading to the morphological and biochemical changes characteristic of apoptosis. Caspase 3 activity is essential for DNA fragmentation, chromatin condensation, and the dismantling of cellular components during cell death. Its function is highly conserved and tightly regulated to maintain cellular homeostasis. | Caspase 3 has been widely used as a biomarker for apoptosis in both experimental and clinical contexts. Detection of active caspase 3 or its cleaved substrates in cells and tissues is commonly employed to assess the extent of apoptotic cell death, particularly in studies of cancer, neurodegenerative diseases, and tissue injury. Immunohistochemical staining, Western blotting, and activity assays targeting caspase 3 are standard methods for evaluating apoptosis levels. The presence of activated caspase 3 can provide information about disease progression, response to therapy, and the effectiveness of pro-apoptotic treatments. |
| interferon gamma (IFNG) | Interferon gamma (IFNG) is a cytokine primarily produced by activated T lymphocytes (notably Th1 cells), natural killer (NK) cells, and certain antigen-presenting cells. It plays a central role in innate and adaptive immunity by promoting the activation of macrophages, enhancing antigen presentation, and stimulating the expression of major histocompatibility complex (MHC) molecules. IFNG is critical for host defense against intracellular pathogens, such as viruses, certain bacteria, and protozoa. It also modulates the differentiation and function of various immune cell types and has regulatory effects on cell proliferation and apoptosis. | IFNG is used as a biomarker to assess cellular immune responses, particularly in the context of infections and immunological disorders. Measurement of IFNG release or expression is applied in diagnostic assays such as interferon-gamma release assays (IGRAs) for detecting latent or active tuberculosis infection. Additionally, IFNG levels are monitored in research and clinical settings to evaluate immune activation, monitor response to immunotherapies, and investigate immune-mediated diseases. |
| interleukin 1 beta (IL1B) | Interleukin 1 beta (IL1B) is a pro-inflammatory cytokine produced predominantly by activated macrophages, as well as other cell types such as monocytes, dendritic cells, and epithelial cells. IL1B plays a central role in the regulation of immune and inflammatory responses. Upon stimulation, it is synthesized as an inactive precursor (pro-IL1B) and subsequently cleaved by caspase-1 within the inflammasome complex to generate the active, secreted form. IL1B exerts its effects by binding to the interleukin-1 receptor (IL-1R), leading to activation of intracellular signaling pathways such as NF-κB and MAPK. This results in the induction of various genes involved in inflammation, fever, cell proliferation, differentiation, and apoptosis. IL1B is critical in host defense against pathogens, but dysregulated production is associated with chronic inflammation and several autoimmune and autoinflammatory conditions. | IL1B is measured in biological fluids such as serum, plasma, and synovial fluid as an indicator of inflammatory activity. Its levels have been utilized as a biomarker in the context of infectious diseases, autoimmune disorders, and inflammatory conditions, including rheumatoid arthritis, sepsis, and inflammatory bowel disease. Elevated IL1B concentrations can reflect ongoing inflammatory processes and have been associated with disease severity or activity in certain contexts. Quantification of IL1B is also used in research to assess immune response and the efficacy of anti-inflammatory therapies. |
| interleukin 6 (IL6) | Interleukin 6 (IL6) is a multifunctional cytokine produced by various cell types, including T cells, B cells, macrophages, fibroblasts, and endothelial cells. IL6 plays a central role in the regulation of immune responses, acute-phase reactions, hematopoiesis, and inflammation. It promotes the differentiation of B cells into antibody-producing plasma cells, stimulates the production of acute-phase proteins in the liver, and influences the differentiation and activation of T cells. Additionally, IL6 is involved in the regulation of metabolic, regenerative, and neural processes. Its expression is tightly controlled under normal physiological conditions but can be markedly upregulated in response to infection, injury, or other inflammatory stimuli. | IL6 is utilized as a biomarker for the assessment of inflammation and immune activation in various clinical contexts. Elevated levels of IL6 in serum or plasma have been associated with infectious diseases, autoimmune disorders, sepsis, and certain cancers. Measurement of IL6 concentrations can aid in the evaluation of disease severity and progression, particularly in conditions characterized by systemic inflammation, such as rheumatoid arthritis, COVID-19, and cytokine release syndromes. IL6 is also used in research settings to monitor the effects of therapeutic interventions targeting inflammatory pathways. |
| nitric oxide synthase 2 (NOS2) | Nitric oxide synthase 2 (NOS2), also known as inducible nitric oxide synthase (iNOS), is an enzyme responsible for catalyzing the production of nitric oxide (NO) from L-arginine in response to inflammatory stimuli. Unlike the constitutive forms of NOS (NOS1 and NOS3), NOS2 is typically not expressed under basal conditions but is induced in various cell types, particularly macrophages and other immune cells, upon exposure to pro-inflammatory cytokines, bacterial lipopolysaccharide, or other immune stimuli. The NO produced by NOS2 plays a critical role in host defense mechanisms, including antimicrobial and antitumor activities, through its cytotoxic and signaling properties. Additionally, NOS2-derived NO can modulate vascular tone, neurotransmission, and immune cell function, and is involved in the pathophysiology of inflammatory and immune-mediated diseases. | NOS2 expression or activity has been utilized as a biomarker to indicate the presence and extent of inflammatory responses in various physiological and pathological contexts. Elevated NOS2 levels have been observed in conditions such as sepsis, autoimmune diseases, chronic inflammatory disorders, and certain cancers. Measurement of NOS2 mRNA, protein, or enzymatic activity in tissues or biological fluids can provide information about the activation state of immune cells and the local or systemic inflammatory milieu. NOS2 has also been studied as a marker for macrophage activation and for monitoring responses to anti-inflammatory therapies. |
| prostaglandin-endoperoxide synthase 2 (PTGS2) | Prostaglandin-endoperoxide synthase 2 (PTGS2), also known as cyclooxygenase-2 (COX-2), is an inducible enzyme that plays a central role in the biosynthesis of prostanoids, including prostaglandins, prostacyclin, and thromboxane. PTGS2 catalyzes the conversion of arachidonic acid to prostaglandin H2, a key step in the inflammatory response. Unlike the constitutively expressed PTGS1 (COX-1), PTGS2 expression is typically low under normal physiological conditions but is rapidly upregulated in response to pro-inflammatory stimuli, cytokines, growth factors, and tumor promoters. PTGS2-mediated prostaglandin production is involved in inflammation, pain, fever, and regulation of cell proliferation and apoptosis. | PTGS2 expression has been utilized as a biomarker in various contexts, particularly in inflammation and oncology. Elevated PTGS2 levels have been observed in inflamed tissues and in several types of cancers, including colorectal, breast, and lung cancers. Its expression is often assessed to characterize inflammatory status or tumor microenvironment, and to evaluate the effects of anti-inflammatory therapies. In oncology, PTGS2 immunohistochemical staining is used to study its association with tumor progression, angiogenesis, and prognosis. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF), also known as TNF-alpha, is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as by other immune cells such as T lymphocytes and natural killer cells. TNF plays a central role in the regulation of immune responses, inflammation, and apoptosis. It mediates its effects by binding to TNF receptors (TNFR1 and TNFR2) on target cells, leading to the activation of intracellular signaling pathways such as NF-κB and MAPK. These pathways result in the expression of genes involved in inflammation, cell survival, and cell death. TNF is involved in the pathogenesis of various inflammatory and autoimmune diseases, and contributes to host defense mechanisms against infections and malignancies. | TNF is utilized as a biomarker for the assessment of inflammatory activity in various conditions, including autoimmune diseases (such as rheumatoid arthritis and inflammatory bowel disease), infectious diseases, and sepsis. Measurement of TNF levels in serum, plasma, or other biological fluids can provide information about the presence and degree of systemic or localized inflammation. TNF concentrations are also monitored in research and clinical studies evaluating the response to anti-TNF therapies and other immunomodulatory treatments. |
Explore Research Opportunities with Ace Therapeutics. Our biomarker research services are designed to advance preclinical drug discovery for Shock by leveraging state-of-the-art analytical platforms and a comprehensive panel of research biomarkers. Please note: all biomarkers discussed are research targets only and are not claimed as validated or mandatory for any application. We focus exclusively on the exploratory and research phases of biomarker analysis, supporting scientific innovation and objective discovery in preclinical development.
We invite you to connect with Ace Therapeutics to discuss collaborative opportunities in exploratory biomarker research for Shock. Let’s advance scientific understanding together through open knowledge exchange and objective, preclinical investigation.
Make Order
Experimental Scheme
Implementation
Conclusion
